Gregory Riely
Memorial Sloan Kettering Cancer · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gregory Riely as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06582771 · A Study of Sotorasib in People With Non-Small Cell Lung CancerMemorial Sloan Kettering Cancer Center · recruiting · Non Small Lung Cancer · principal investigator
- Ph1/Ph2NCT06007937 · A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Non Small Cell Lung Cancer, Metastatic, Recurrent · principal investigator
- Ph1NCT03681483 · RO5126766 for Patients With Advanced KRAS-Mutant Lung CancerMemorial Sloan Kettering Cancer Center · completed · Advanced Non-small Cell Lung Cancer · principal investigator
- Ph2NCT01833143 · Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12DMemorial Sloan Kettering Cancer Center · completed · Non-Small Cell Lung Cancer · principal investigator
- N/ANCT01300429 · Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene LocusMemorial Sloan Kettering Cancer Center · completed · Lung Cancer · principal investigator
- Ph1/Ph2NCT00716456 · Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to ErlotinibMemorial Sloan Kettering Cancer Center · completed · Lung Adenocarcinoma · principal investigator
- Ph1NCT00606814 · Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid TumorsInfinity Pharmaceuticals, Inc. · completed · Solid Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:52 UTC. The ranking covers the 200 most relevant of 57 PubMed records, and a shared surname and initials can bring in a namesake. All 57 on PubMed
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med · 20132,837 citationsRCR 78.7
- Crizotinib in ROS1-rearranged non-small-cell lung cancer.N Engl J Med · 20141,567 citationsRCR 42.3
- Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med · 20141,179 citationsRCR 32.9
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol · 20121,021 citationsRCR 26.5
- Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.N Engl J Med · 2022912 citationsRCR 57.5
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.Lancet Oncol · 2018642 citationsRCR 21.1
- Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res · 2006628 citationsRCR 12.5
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.Nat Med · 2019617 citationsRCR 19.6
- 586 citationsRCR 16.0
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.Lancet Oncol · 2016533 citationsRCR 16.5